Filtering by:
Targeted TherapyFDA Approves a Biosimilar to Avastin for Cancer Treatment
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) as the first biosimilar drug for treating cancer. It works the same way as Avastin (bevacizumab).
FDA Approves Mylotarg (Gemtuzumab Ozogamicin) for Acute Myeloid Leukemia
The US Food and Drug Administration (FDA) has approved Mylotarg (gemtuzumab ozogamicin) for adults and children with certain types of acute myeloid leukemia (AML).
FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults
The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment.
FDA Approves Idhifa (Enasidenib) for Acute Myeloid Leukemia
The US Food and Drug Administration (FDA) has approved the use of the targeted therapy drug Idhifa (enasidenib) to treat adults who have a specific type of acute myeloid leukemia (AML).